Transcriptional repression of mad-max complex by human umbilical cord blood stem cells downregulates extracellular signal-regulated kinase in glioblastoma

Stem Cells and Development

Volumn 21, Issue 10, 2012, Pages 1779-1793

  Velpula, Kiran Kumar ^a   Dasari, Venkata Ramesh ^a   Tsung, Andrew J ^a   Dinh, Dzung H ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 10074 G 5; ALPHA9 BETA1 INTEGRIN; CELL SURFACE RECEPTOR; CYCLIN D1; FOCAL ADHESION KINASE; INTEGRIN; MAX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYC PROTEIN; PROTEIN MAD1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL CYCLE PROGRESSION; CELL NUCLEUS; COCULTURE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOPLASM; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA TRANSLATION; STEM CELL;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIGENS, CD29; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CORD BLOOD STEM CELL TRANSPLANTATION; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FETAL BLOOD; FOCAL ADHESION KINASE 1; G1 PHASE CELL CYCLE CHECKPOINTS; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHA CHAINS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION, GENETIC;

EID: 84862842906     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0424     Document Type: Article

References (44)

1. Lang FF, JM Bruner, GN Fuller, K Aldape, MD Prados, S Chang, MS Berger, MW McDermott, SM Kunwar, et al. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21:2508-2518.
2. Steelman LS, SC Pohnert, JG Shelton, RA Franklin, FE Bertrand and JA McCubrey. (2004). JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218.
3. Chang F, LS Steelman, JT Lee, JG Shelton, PM Navolanic, WL Blalock, RA Franklin and JA McCubrey. (2003). Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263-1293.
4. Cobb MH and EJ Goldsmith. (1995). How MAP kinases are regulated. J Biol Chem 270:14843-14846.
5. McCubrey JA, LS Steelman, RA Franklin, SL Abrams, WH Chappell, EW Wong, BD Lehmann, DM Terrian, J Basecke, et al. (2007). Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul 47:64-103.
6. Coller HA, C Grandori, P Tamayo, T Colbert, ES Lander, RN Eisenman and TR Golub. (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 97:3260-3265.
7. Daksis JI, RY Lu, LM Facchini, WW Marhin and LJ Penn. (1994). Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9:3635-3645.
8. Jansen-Durr P, A Meichle, P Steiner, M Pagano, K Finke, J Botz, J Wessbecher, G Draetta and M Eilers. (1993). Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A 90:3685-3689.
9. Adhikary S and M Eilers. (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6:635-645.
10. Schreiber-Agus N, D Stein, K Chen, JS Goltz, L Stevens and RA DePinho. (1997). Drosophila Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype. Proc Natl Acad Sci U S A 94:1235-1240.
11. Velpula KK, VR Dasari, AJ Tsung, CS Gondi, JD Klopfenstein, S Mohanam and JS Rao. (2011). Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1. PLoS One 6:e18017.
12. Rao JS, P Bhoopathi, C Chetty, M Gujrati and SS Lakka. (2007). Matrix metalloproteinase-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16INK4 and mitogen-activated protein kinase pathway. Cancer Res 67:4956-4964.
13. Lenormand G, S Henon, A Richert, J Simeon and F Gallet. (2003). Elasticity of the human red blood cell skeleton. Biorheology 40:247-251.
14. Sato T and A Miwa. (2002). Ets-1 and integrin beta3 for lung metastasis from colorectal cancer. APMIS 110:347-353.
15. Wei J, S Zhou, MG Bachem, KM Debatin and C Beltinger. (2007). Infiltration of blood outgrowth endothelial cells into tumor spheroids: role of matrix metalloproteinases and irradiation. Anticancer Res 27:1415-1421.
16. Zhao J, R Pestell and JL Guan. (2001). Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression. Mol Biol Cell 12:4066-4077.
17. Schaller MD, JD Hildebrand and JT Parsons. (1999). Complex formation with focal adhesion kinase: A mechanism to regulate activity and subcellular localization of Src kinases. Mol Biol Cell 10:3489-3505.
18. Schlaepfer DD, KC Jones and T Hunter. (1998). Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src-and focal adhesion kinase-initiated tyrosine phosphorylation events. Mol Cell Biol 18:2571-2585.
19. Srinivasan R, T Zabuawala, H Huang, J Zhang, P Gulati, S Fernandez, JC Karlo, GE Landreth, G Leone and MC Ostrowski. (2009). Erk1 and Erk2 regulate endothelial cell proliferation and migration during mouse embryonic angiogenesis. PLoS One 4:e8283.
20. Banerjee A, J Hu and DJ Goss. (2006). Thermodynamics of protein-protein interactions of cMyc, Max, and Mad: effect of polyions on protein dimerization. Biochemistry 45:2333-2338.
21. Mauleon I, MN Lombard, MJ Munoz-Alonso, M Canelles and J Leon. (2004). Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of cmyc. Mol Carcinog 39:85-90.
22. Teodorczyk M and A Martin-Villalba. (2010). Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol 222:1-10.
23. Brunet A, D Roux, P Lenormand, S Dowd, S Keyse and J Pouyssegur. (1999). Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factorinduced gene expression and cell cycle entry. EMBO J 18:664-674.
24. Marampon F, GL Gravina, A Di Rocco, P Bonfili, SM Di, C Fardella, L Polidoro, C Ciccarelli, C Festuccia, et al. (2011). MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther 10:159-168.
25. Mendes O, HT Kim, G Lungu and G Stoica. (2007). MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 24:341-351.
26. Zhou HY, YL Pon and AS Wong. (2007). Synergistic effects of epidermal growth factor and hepatocyte growth factor on human ovarian cancer cell invasion and migration: role of extracellular signal-regulated kinase 1/2 and p38 mitogenactivated protein kinase. Endocrinology 148:5195-5208.
27. Su CM, DY Lu, CJ Hsu, HT Chen, CY Huang, WH Yang, YC Su, SN Yang, YC Fong, WP Tseng and CH Tang. (2009). Glial cell-derived neurotrophic factor increases migration of human chondrosarcoma cells via ERK and NF-kappaB pathways. J Cell Physiol 220:499-507.
28. Chiu WT, SC Shen, JM Chow, CW Lin, LT Shia and YC Chen. (2010). Contribution of reactive oxygen species to migration/invasion of human glioblastoma cells U87 via ERK-dependent COX-2/PGE(2) activation. Neurobiol Dis 37:118-129.
29. Liu X, S Yan, T Zhou, Y Terada and RL Erikson. (2004). The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 23:763-776.
30. Keely P, L Parise and R Juliano. (1998). Integrins and GTPases in tumour cell growth, motility and invasion. Trends Cell Biol 8:101-106.
31. Schlaepfer DD, CR Hauck and DJ Sieg. (1999). Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71:435-478.
32. Sieg DJ, CR Hauck and DD Schlaepfer. (1999). Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci 112:2677-2691.
33. Brown MC, I Staniszewska, P Lazarovici, GP Tuszynski, L Del Valle and C Marcinkiewicz. (2008). Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma. Neuro Oncol 10:968-980.
34. Young BA, Y Taooka, S Liu, KJ Askins, Y Yokosaki, SM Thomas and D Sheppard. (2001). The cytoplasmic domain of the integrin alpha9 subunit requires the adaptor protein paxillin to inhibit cell spreading but promotes cell migration in a paxillin-independent manner. Mol Biol Cell 12:3214-3225.
35. Staniszewska I, S Zaveri, L Del Valle, I Oliva, VL Rothman, SE Croul, DD Roberts, DF Mosher, GP Tuszynski and C Marcinkiewicz. (2007). Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res 100:1308-1316.
36. Marampon F, C Ciccarelli and BM Zani. (2006). Downregulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 5:31.
37. Marampon F, G Bossi, C Ciccarelli, A Di Rocco, A Sacchi, RG Pestell and BM Zani. (2009). MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 8:543-551.
38. Ussar S and T Voss. (2004). MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem 279:43861-43869.
39. Mauro A, C Ciccarelli, P De Cesaris, A Scoglio, M Bouche, M Molinaro, A Aquino and BM Zani. (2002). PKCalphamediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci 115:3587-3599.
40. Baudino TA and JL Cleveland. (2001). The Max network gone mad. Mol Cell Biol 21:691-702.
41. McMahon SB, MA Wood and MD Cole. (2000). The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20:556-562.
42. Ayer DE, L Kretzner and RN Eisenman. (1993). Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72:211-222.
43. Hachem A and RB Gartenhaus. (2005). Oncogenes as molecular targets in lymphoma. Blood 106:1911-1923.
44. Chen J, T Willingham, LR Margraf, N Schreiber-Agus, RA DePinho and PD Nisen. (1995). Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat Med 1:638-643.